Rxivist logo

PrP concentration in the central nervous system: regional variability, genotypic effects, and pharmacodynamic impact

By Meredith A Mortberg, Hien T Zhao, Andrew G Reidenbach, Juliana E Gentile, Eric Kuhn, Jill O'Moore, Patrick M. Dooley, Theresa R Connors, Curt Mazur, Shona W Allen, Bianca A Trombetta, Alison McManus, Matthew R Moore, Jiewu Liu, Deborah E Cabin, Holly B Kordasiewicz, Joel Mathews, Steven E Arnold, Sonia M Vallabh, Eric Vallabh Minikel

Posted 01 Nov 2021
medRxiv DOI: 10.1101/2021.11.01.21265619

Reliable and scalable quantification of prion protein (PrP) is vital to the development of PrP- lowering drugs for prion disease. Here we develop a plate-based immunoassay reactive for PrP across six species of interest and applicable to brain and cerebrospinal fluid (CSF). Brain PrP shows similar patterns of regional variation in mice, cynomolgus macaques and humans. CSF PrP concentration does not appear to differ according to age, sex, or common PRNP variants, but it is reduced in the presence of rare pathogenic PRNP variants, with carriers of P102L displaying 55% and of D178N just 31% the CSF PrP concentration of mutation-negative controls. In rodents, pharmacologic reduction of brain Prnp RNA is reflected in brain parenchyma PrP, and in turn in CSF PrP. Our findings support the use of CSF PrP as a pharmacodynamic biomarker for PrP-lowering drugs, and suggest that relative reduction from individual baseline CSF PrP concentration may be an appropriate marker for target engagement.

Download data

  • Downloaded 288 times
  • Download rankings, all-time:
    • Site-wide: 141,616
    • In neurology: 734
  • Year to date:
    • Site-wide: 35,207
  • Since beginning of last month:
    • Site-wide: 82,289

Altmetric data

Downloads over time

Distribution of downloads per paper, site-wide